Trial Profile
A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 25 Feb 2022
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary) ; Iodine radioactive; Thyrotropin alfa
- Indications Carcinoma; Thyroid cancer
- Focus Registrational; Therapeutic Use
- Acronyms ASTRA
- Sponsors AstraZeneca
- 22 Feb 2022 Results published in the Journal of Clinical Oncology
- 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 27 Aug 2019 Status changed to discontinued.